Compare TG Therapeutics Inc (TGTX) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.76 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 20.6× TG Therapeutics Inc's market cap, and Vanguard Emerging Markets Stock Index Fund ETF is more actively traded (9,650,999 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| TGTX | VWO | |
|---|---|---|
Market Cap | $8.16B | $168.50B |
Volume | 1,735,121 | 9,650,999 |
Sector | Health | — |
52-Week High | $59.06 | $61.44 |
52-Week Low | $26.94 | $52.42 |
Typical Hold Time | 16 Days | 135 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
VWO trades at $59.76, down 0.15% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure. The ETF's emerging markets focus faces headwinds from China's economic slowdown, though AI-driven semiconductor demand in Taiwan provides some offset. Recent institutional buying by firms like Allianz and Alamar Capital suggests confidence in long-term emerging markets exposure despite near-term challenges.
The outlook remains cautious given China's persistent weakness and technical bearish signals, though institutional accumulation and AI infrastructure spending offer potential catalysts. Key risks include concentrated emerging markets exposure and currency volatility, requiring careful position sizing for investors seeking diversification beyond developed markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
